Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

Bart Koopman,Harry J.M. Groen,Ed Schuuring,T. Jeroen N. Hiltermann,Wim Timens,Wilfred F.A. den Dunnen,Anke van den Berg,Arja ter Elst,Michel van Kruchten,Joost L. Kluiver,Birgitta I. Hiddinga,Lucie B.M. Hijmering-Kappelle,Matthew R. Groves,Juliana F. Vilacha,Léon C. van Kempen,Anthonie J. van der Wekken

Clinical Lung Cancer（2022）

引用 6|浏览21

暂无评分

摘要

Molecular diagnostics performed on tissue samples that are refractive to ALK inhibitor therapy can reveal new options for targeted therapy for NSCLC patients. Our comprehensive overview of clinical evidence of drug actionability of ALK on-target resistance mechanisms may serve as a practical guide to select the most optimal drug for individual patients.

查看译文

关键词

ALK,Non-small cell lung cancer,Mutation,Resistance,Sensitivity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要